Madrigal Pharmaceuticals enters the final week of September with a fresh analyst initiation pulling in one direction and a month-long rise in short positioning pulling in the other.
Citi's Eric Joseph launched coverage this week with a Buy rating and a $725 target — the most timely piece of analyst activity on MDGL right now. The broader Street is constructively aligned: 14 buys, a consensus Buy rating, and a mean price target of $680.82, which implies roughly 31% upside to Tuesday's close of $518.83. That said, there is genuine dispersion in the targets. Barclays holds an Overweight with a $962 target, sitting well above the pack, while BofA remains the outlier with a Neutral and a $542 target — barely above where the stock is trading. The bull case rests on Rezdiffra, the first approved MASH treatment, with estimated peak sales of $8.9 billion cited for the mid-2030s and a recent exclusive licensing deal for ARO-PNPLA3 adding pipeline optionality. Bears point to incoming competition in the MASH space and the drag that rival entry puts on long-run revenue assumptions.
Short positioning complicates the picture. Bears have been building steadily for a month — short interest as a percentage of free float has climbed to just over 10%, up roughly 17% from where it was 30 days ago, even as it edged fractionally lower on the week. That 10% level is meaningful for a stock with MDGL's liquidity profile and puts the short book near 2.27 million shares, with FINRA's official fortnightly print confirming 2.24 million shares shorted as of end-August and a days-to-cover reading of 9.5 — heavy enough that any sustained buying pressure would take time to absorb. The cost to borrow remains inexpensive at 0.44%, a marginal nudge higher on the week, and availability is exceptionally loose at over 1,800% — meaning there is roughly 18 times as much stock available to lend as there is currently shorted. The borrow market is not strained in any way. Shorts can keep adding without friction.
Options positioning has quietly shifted more defensive. The put/call ratio at 0.45 is running more than two standard deviations above its 20-day average of 0.43 — a small absolute number, but statistically notable given how tight the recent range has been. The ratio touched its lowest levels of the past year in early September before reversing; the uptick over the past two sessions coincides with the short interest rebuild and suggests some hedging activity has returned. The 52-week PCR high is 0.76, so there is nothing extreme here, but the directional shift from a month of near-historically-low put buying back toward a more hedged stance is worth noting.
The stock's two founders — Paul Friedman and Rebecca Taub — filed Schedule 13D/A amendments in December, each holding 7.8% stakes. Those filings carry activist-flag status on SEC's register, though the positions appear unchanged since the amendment. This is a material fact: two of the original architects of Rezdiffra hold meaningful, disclosed stakes with activist designations on the register. Separately, the CEO William Sibold sold approximately $2.1 million of stock on September 11 across a series of transactions, all executed under a pre-arranged 10b5-1 plan — planned disposals of this kind are standard for executive compensation management and carry far less signal than discretionary selling, but the context is worth carrying. Net insider selling over the past 90 days totals nearly $7.9 million in value.
Earnings landed twice in recent history worth noting. August's print produced a +6.7% one-day move. The July 30 report went the other way sharply, with the stock falling nearly 14.5% in a single session before recovering to a -6.7% result by the five-day mark. The next scheduled print is November 3 — six weeks out. With short interest at 10% of the float, a 9.5-day cover requirement, and the Citi initiation landing this week, how quickly Rezdiffra's commercial trajectory develops between now and that date becomes the central question for the positioning debate.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
